Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Core Insights - Aytu BioPharma, Inc. held an Investor Day on January 20, 2026, focusing on its product EXXUA, the first FDA-approved 5HT1a agonist for major depressive disorder (MDD) [1][3][23] Group 1: EXXUA Overview - EXXUA is a novel oral selective serotonin 5-HT1A receptor agonist indicated for the treatment of MDD in adults [73] - The product was launched on December 15, 2025, and the full commercial launch is now underway [25][26] - The U.S. MDD market exceeds $22 billion, with over 345 million prescriptions written annually for antidepressants [24] Group 2: Clinical Insights - An estimated 21 million adults in the U.S. had at least one major depressive episode in 2021, representing 8.3% of all U.S. adults [9] - 50% to 60% of patients fail to achieve remission with first-line SSRIs, and nearly half discontinue their first-line treatment due to side effects [11][12] - EXXUA does not carry a warning about the risk of sexual dysfunction, unlike many antidepressants, and demonstrates a neutral sexual profile in clinical studies [13][26] Group 3: Clinical Trial Data - In pivotal studies, EXXUA demonstrated statistically significant improvement in the Hamilton Depression Rating Scale (HAM-D17) total score at Week 8 compared to placebo [15][19] - The mean increase in body weight with EXXUA was 1 kg compared to 0 kg with placebo in pivotal Study 1, and 0.3 kg compared to 0.1 kg in Study 2 [14] - The most common adverse reactions were dizziness, nausea, insomnia, abdominal pain, and dyspepsia, with a discontinuation rate of 7% for EXXUA due to adverse events [19][22][101] Group 4: Commercialization Strategy - Aytu's commercialization agreement for EXXUA includes a $3 million upfront payment and additional payments based on sales milestones [27][28] - The company has a comprehensive launch strategy focused on prescriber adoption and brand growth, leveraging a virtual sales team and a patient access program [46][62] - Aytu aims to deliver nearly 20,000 customer contacts during the initial launch phase, targeting high-volume prescribers of antidepressants [61][52] Group 5: Financial Highlights - Aytu reported $32.6 million in cash as of September 30, 2025, with no additional cash requirement expected through profitability [35][36] - The expected gross margin for EXXUA is 66-68%, compared to a company-wide gross margin of 67.6% [40][41] - The original launch investment budget for EXXUA was reduced from $10 million to $6-8 million due to efficiencies [39]